These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
25. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309 [TBL] [Abstract][Full Text] [Related]
26. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161 [TBL] [Abstract][Full Text] [Related]
27. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812 [TBL] [Abstract][Full Text] [Related]
28. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses. Kuang Y; Weng X; Liu X; Zhu H; Chen Z; Jiang B; Chen H Cancer Lett; 2010 Jul; 293(2):254-62. PubMed ID: 20149524 [TBL] [Abstract][Full Text] [Related]
29. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687 [TBL] [Abstract][Full Text] [Related]
30. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211 [TBL] [Abstract][Full Text] [Related]
31. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice]. Tan G; Wang ZY; Yin S Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530 [TBL] [Abstract][Full Text] [Related]
32. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Loskog A; Tötterman TH; Böhle A; Brandau S Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026 [TBL] [Abstract][Full Text] [Related]
33. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
34. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500 [TBL] [Abstract][Full Text] [Related]
35. Functional modification of dendritic cells with recombinant adenovirus encoding interleukin 10 for the treatment of sepsis. Oberholzer A; Oberholzer C; Efron PA; Scumpia PO; Uchida T; Bahjat K; Ungaro R; Tannahill CL; Murday M; Bahjat FR; Tsai V; Hutchins B; Moldawer LL; Laface D; Clare-Salzler MJ Shock; 2005 Jun; 23(6):507-15. PubMed ID: 15897802 [TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma. Xie J; Xiong L; Tao X; Li X; Su Y; Hou X; Shi H Lung Cancer; 2010 Jun; 68(3):338-45. PubMed ID: 19671483 [TBL] [Abstract][Full Text] [Related]
37. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766 [TBL] [Abstract][Full Text] [Related]
38. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Hu J; Yuan X; Belladonna ML; Ong JM; Wachsmann-Hogiu S; Farkas DL; Black KL; Yu JS Cancer Res; 2006 Sep; 66(17):8887-96. PubMed ID: 16951206 [TBL] [Abstract][Full Text] [Related]
39. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency. Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483 [TBL] [Abstract][Full Text] [Related]
40. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]